Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways

Journal of Biological Chemistry

Volumn 287, Issue 11, 2012, Pages 8297-8309

  Zhuang, Min ^a,b   Wang, Wei ^a   De Feo, Christopher J ^a   Vassell, Russell ^a   Weiss, Carol D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COILED COIL; DOMINANT NEGATIVE; EQUAL PROBABILITY; FUSION PROTEINS; GAIN INSIGHT; GENETIC PATHWAYS; HEPTAD REPEAT REGIONS; INHIBITOR DESIGN; PEPTIDE FUSION; PEPTIDE INHIBITORS; REFOLDING; TRIMERIZATION; VIRUS ENTRY;

CELL MEMBRANES; CYTOLOGY; DIMERS; DISEASES; PEPTIDES;

VIRUSES;

GLYCOPROTEIN GP 41; PEPTIDE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMOSTABILITY; VIRUS ENTRY; VIRUS RESISTANCE;

CELL LINE; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MUTATION; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863270623     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.324483     Document Type: Article

References (45)

1. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810 (Pubitemid 32662225)
2. Melikyan, G. B. (2011) Membrane fusion mediated by human Immunodeficiency virus envelope glycoprotein. Curr. Top. Membr. 86, 81-106
3. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (Pubitemid 27199898)
4. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (Pubitemid 27227210)
5. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A. 94, 12303-12308 (Pubitemid 27492523)
6. Caffrey, M., Cai, M., Kaufman, J., Stahl, S. J., Wingfield, P. T., Covell, D. G., Gronenborn, A. M., and Clore, G. M. (1998) Three-dimensional solution structure of the 44-kDa ectodomain of SIV gp41. EMBO J. 17, 4572-4584 (Pubitemid 28377158)
7. Yang, Z. N., Mueser, T. C., Kaufman, J., Stahl, S. J., Wingfield, P. T., and Hyde, C. C. (1999) The crystal structure of the SIV gp41 ectodomain at 1.47 Å resolution. J. Struct. Biol. 126, 131-144 (Pubitemid 29402579)
8. Furuta, R. A., Wild, C. T., Weng, Y., and Weiss, C. D. (1998) Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276-279 (Pubitemid 28164878)
9. He, Y., Vassell, R., Zaitseva, M., Nguyen, N., Yang, Z., Weng, Y., and Weiss, C. D. (2003) Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J. Virol. 77, 1666-1671 (Pubitemid 36113245)
10. Koshiba, T., and Chan, D. C. (2003) The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J. Biol. Chem. 278, 7573-7579 (Pubitemid 36800765)
11. Chan, D. C., and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684 (Pubitemid 28257575)
12. Baldwin, C. E., Sanders, R. W., and Berkhout, B. (2003) Inhibiting HIV-1 entry with fusion inhibitors. Curr. Med. Chem. 10, 1633-1642 (Pubitemid 37038590)
13. Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., and Jiang, S. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282, 9612-9620 (Pubitemid 47104580)
14. Kilgore, N. R., Salzwedel, K., Reddick, M., Allaway, G. P., and Wild, C. T. (2003) Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virol. 77, 7669-7672 (Pubitemid 36734537)
15. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents. Chemother. 46, 1896-1905 (Pubitemid 34535213)
16. Poveda, E., Rodés, B., Toro, C., Martín-Carbonero, L., Gonzalez-Lahoz, J., and Soriano, V. (2002) Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. Aids 16, 1959-1961
17. Greenberg, M. L., and Cammack, N. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340 (Pubitemid 39177450)
18. Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., and Greenberg, M. L. (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79, 12447-12454 (Pubitemid 41346107)
19. Chinnadurai, R., Rajan, D., Münch, J., and Kirchhoff, F. (2007) Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J. Virol. 81, 6563-6572 (Pubitemid 46878060)
20. Eckert, D. M., and Kim, P. S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U.S.A. 98, 11187-11192 (Pubitemid 32928704)
21. Root, M. J., Kay, M. S., and Kim, P. S. (2001) Protein design of an HIV-1 entry inhibitor. Science 291, 884-888 (Pubitemid 32120761)
22. Lu, M., and Kim, P. S. (1997)Atrimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15, 465-471 (Pubitemid 28035859)
23. Lawless, M. K., Barney, S., Guthrie, K. I., Bucy, T. B., Petteway, S. R., Jr., and Merutka, G. (1996) HIV-1 membrane fusion mechanism. Structural studies of the interactions between biologically active peptides from gp41. Biochemistry 35, 13697-13708 (Pubitemid 26359183)
24. Bewley, C. A., Louis, J. M., Ghirlando, R., and Clore, G. M. (2002) Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277, 14238-14245 (Pubitemid 34968038)
25. Caffrey, M., Kaufman, J., Stahl, S., Wingfield, P., Gronenborn, A. M., and Clore, G. M. (1999) Monomer-trimer equilibrium of the ectodomain of SIV gp41. Insight into the mechanism of peptide inhibition of HIV infection. Protein Sci. 8, 1904-1907 (Pubitemid 29430491)
26. Desmezieres, E., Gupta, N., Vassell, R., He, Y., Peden, K., Sirota, L., Yang, Z., Wingfield, P., and Weiss, C. D. (2005) Human immunodeficiency virus (HIV) gp41 escape mutants. Cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J. Virol. 79, 4774-4781 (Pubitemid 40464228)
27. Hope, T. J., McDonald, D., Huang, X. J., Low, J., and Parslow, T. G. (1990) Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator. Essential residues near the amino terminus. J. Virol. 64, 5360-5366 (Pubitemid 20364526)
28. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., and Kabat, D. (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855-2864 (Pubitemid 28175522)
29. Oravecz, T., Roderiquez, G., Koffi, J., Wang, J., Ditto, M., Bou-Habib, D. C., Lusso, P., and Norcross, M. A. (1995) CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. Nat. Med. 1, 919-926
30. Reed, L. J., and Muench, H. (1938) A simple method of estimating fifty percent endpoints. Am. J. Hygiene 27, 493-497
31. Chen, Y. H., Yang, J. T., and Chau, K. H. (1974) Determination of the helix and β form of proteins in aqueous solution by circular dichroism. Biochemistry 13, 3350-3359
32. Shu, W., Liu, J., Ji, H., Radigen, L., Jiang, S., and Lu, M. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39, 1634-1642 (Pubitemid 30108955)
33. Agashe, V. R., and Udgaonkar, J. B. (1995) Thermodynamics of denaturation of barstar. Evidence for cold denaturation and evaluation of the interaction with guanidine hydrochloride. Biochemistry 34, 3286-3299
34. He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., and Dai, Q. (2008) Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure. Implications for designing novel anti- HIV fusion inhibitors. J. Virol. 82, 6349-6358 (Pubitemid 351875113)
35. Wang, W., De Feo, C. J., Zhuang, M., Vassell, R., and Weiss, C. D. (2011) Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41. J. Virol. 85, 12929-12938
36. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (Pubitemid 28289647)
37. Holland, A. U., Munk, C., Lucero, G. R., Nguyen, L. D., and Landau, N. R. (2004) α-Complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319, 343-352 (Pubitemid 38251274)
38. Izumi, K., Nakamura, S., Nakano, H., Shimura, K., Sakagami, Y., Oishi, S., Uchiyama, S., Ohkubo, T., Kobayashi, Y., Fujii, N., Matsuoka, M., and Kodama, E. N. (2010) Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Res. 87, 179-186
39. Lu, M., Blacklow, S. C., and Kim, P. S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2, 1075-1082
40. Caffrey, M. (2001) Model for the structure of the HIV gp41 ectodomain. Insight into the intermolecular interactions of the gp41 loop. Biochim. Biophys. Acta 1536, 116-122
41. Hamburger, A. E., Kim, S., Welch, B. D., and Kay, M. S. (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280, 12567-12572
42. Steger, H. K., and Root, M. J. (2006) Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281, 25813-25821 (Pubitemid 44401969)
43. Welch, B. D., Francis, J. N., Redman, J. S., Paul, S., Weinstock, M. T., Reeves, J. D., Lie, Y. S., Whitby, F. G., Eckert, D. M., Hill, C. P., Root, M. J., and Kay, M. S. (2010) Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84, 11235-11244
44. Deleted in proof
45. Haim, H., Strack, B., Kassa, A., Madani, N., Wang, L., Courter, J. R., Princiotto, A., McGee, K., Pacheco, B., Seaman, M. S., Smith, A. B., 3rd, and Sodroski, J. (2011) Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 7, e1002101